Phase I/II study of S-IROX as second-line therapy after nab-Paclitaxel + Gemcitabine for unresectable pancreatic cancer
Not Applicable
- Conditions
- The unresectable advanced pancreatic cancer after first-line Nab-Paclitaxel+Gemcitabine failure
- Registration Number
- JPRN-UMIN000036969
- Lead Sponsor
- Gifu Municipal Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
Pulmonary fibrosis or interstitial pneumonia Watery stool Infection Uncontrolled diabetes mellitus Any serious complication Pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Overall survival Progression free survival The frequency of occurrence of complication